Skip to main content Accessibility help
  • Print publication year: 2009
  • Online publication date: July 2009

22 - Diagnosis and treatment of graft-versus-host-disease

Related content

Powered by UNSILO
Further reading
Antin, JH, et al. 2003. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102(5): 1601–05.
Arai, S, et al. 2002. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8(3): 155–60.
Arora, M, et al. 2001. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 7(5): 265–73.
Bacigalupo, A, et al. 2001. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98(10): 2942–47.
Basara, N., et al., 2000 Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 14(2): 121–6.
Chao, NJ, Schmidt, GM, Niland, JC, et al. 1993. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329: 1225–30.
Chao, NJ, Schlegel, PG. 1995. Prevention and treatment of graft-versus-host disease. Ann N Y Acad Sci 770: 130–40.
Chao, NJ, et al. 2000. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 6(3): 254–61.
Couriel DR, C. A., Saliba, R, Ghosh, S, et al. 2003. Graft-Versus-Host Disease of the Liver: A Clinicopathological Analysis. Blood 102(11): 712a.
Couriel, D, et al. 2004. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101(9): 1936–46.
Couriel, DR, et al. 2004. Tumor necrosis factor alpha blockade for the treatment of steroid-refractory acute GVHD. Blood. 104: 649–54.
Couriel, DR, et al. 2005. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130(3): 409–17.
Couriel, D, et al. 2006. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12(4): 375–96.
Couriel, DR, et al. 2006. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107(8): 3074–80.
Cutler, C, et al. 2006. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108(2): 756–62.
Filipovich, AH, Weisdorf, D, Pavletic, S, et al. 2005. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 11: 945–56.
Goker, H, Haznedaroglu, IC, Chao, NJ. 2001. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29(3): 259–77.
Greinix, HT, et al. 1998. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 92(9): 3098–104.
Greinix, HT, et al., 2000. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 96(7): p. 2426–31.
Greinix, HT, et al. 2006. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 91(3): 405–08.
Hings, IM, et al. 1993. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation 56(3): 577–80.
Ho, VT, et al. 2004. Safety and efficacy of denileukin diftitox in patients with steroid refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 104: 1224–6.
Hsu, B, et al. 2001. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 28(10): 945–50.
Hymes, SR, et al. 2006. Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant 12(11): 1101–13.
Jabs, DA, et al. 1989. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol 107(9): 1343–48.
Jacobsohn, DA and Vogelsang, GB. 2002. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 62(6): 879–89.
Junghans, RP, et al. 1990. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50(5): 1495–502.
Khoury, H, et al. 2001. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 27(10): 1059–64.
Koc, S, et al. 2002. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 100(1): 48–51.
Lee, SJ, et al. 2002. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100(2): 406–14.
Lee, SJ, Vogelsang, G, Flowers, ME. 2003. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9(4): 215–33.
Lee, SJ, et al. 2004. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104(5): 1559–64.
Lee, HJ, et al. 2006. Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 38(4): 299–303.
Maloney, DG, et al. 2003. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102(9): 3447–54.
Martin, PJ, et al. 1990. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76(8): 1464–72.
Martin, PJ, et al. 1991. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77(8): 1821–28.
Marty, FM, et al. 2003. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102(8): 2768–76.
Mielcarek, M, et al. 2003. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102(2): 756–62.
Nash, RA, et al. 2000. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96(6): 2062–68.
Przepiorka, D, et al. 1995. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6): 825–28.
Przepiorka, D, et al. 1999. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 5(2): 94–97.
Przepiorka, D, et al. 2000. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95(1): 83–89.
Ratanatharathorn, V, et al. 1998. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92(7): 2303–14.
Reimold, AM. 2003. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 325(2): 75–92.
Saliba, RM, et al. 2007. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 109(7): 2751–58.
Scallon, BJ, et al. 1995. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7(3): 251–59.
Shlomchik, WD, et al. 2007. Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 13(1 Suppl 1): 2–10.
Stewart, BL, et al. 2004. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104(12): 3501–06.
Vogelsang, GB. 2000. Advances in the treatment of graft-versus-host disease. Leukemia 14(3): 509–10.